Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study

被引：1
|
作者：
Oppenheimer, Federico [1 ]
Russ, Graeme [2 ]
Viklicky, Ondrej [3 ]
Oberbauer, Rainer [4 ]
Garcia, Valter [5 ]
Witzke, Oliver [6 ]
Kuypers, Dirk [7 ]
Danguilan, Romina [8 ]
Das Gupta, Ayan [9 ]
Bernhardt, Peter [10 ]
Sommerer, Claudia [11 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Royal Adelaide Hosp, Adelaide, SA, Australia
[3] IKEM, Prague, Czech Republic
[4] Med Univ Vienna, Vienna, Austria
[5] Santa Casa Misericordia Porto Alegre, Porto Alegre, RS, Brazil
[6] Univ Klinikum Essen, Essen, Germany
[7] Gasthuisberg Univ Hosp, Leuven, Belgium
[8] Natl Kidney & Transplant Inst, Quezon City, Philippines
[9] Novartis Healthcare Pvt Ltd, Hyderabad, India
[10] Novartis Pharma AG, Basel, Switzerland
[11] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
TRANSPLANTATION | 2018年 / 102卷
关键词：
D O I：
10.1097/01.tp.0000543112.91427.9d
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
591.2
引用
收藏
页码：S363 / S363
页数：1
相关论文
共 50 条
  • [41] EFFICACY, RENAL FUNCTION AND SAFETY OF EVEROLIMUS [EVR] WITH REDUCED-DOSE CALCINEURIN INHIBITOR [RCNI] IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS [KTXR]: M24 RESULTS
    Albano, L.
    Buchler, M.
    Pernin, V.
    Vuiblet, V.
    Bernhardt, P.
    Hernandez-Gutierrez, P.
    Capela, D.
    Gharbi, H.
    Legendre, C.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 12 - 12
  • [42] Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study (vol 103, pg 1953, 2019)
    Tedesco-Silva
    TRANSPLANTATION, 2020, 104 (05) : E142 - E142
  • [43] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED-EXPOSURE CYCLOSPORINE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: 24-MONTH ANALYSIS FROM THE TRANSFORM STUDY
    Sommerer, Claudia
    Pinchuk, Aleksey
    Aleman, Silvina
    Vuiblet, Vincent
    Van der Giet
    Amante, Angel Joaquin
    Han, Duck Jong
    Huynh-Do, Uyen
    Ingsathit, Atiporn
    Gawai, Apurva
    Gutierrez, Maria Pilar Hernandez
    Carmellini, Mario
    TRANSPLANTATION, 2020, 104 (09) : S622 - S623
  • [44] Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study
    Watarai, Yoshihiko
    Danguilan, Romina
    Casasola, Concesa
    Chang, Shen-Shin
    Ruangkanchanasetr, Prajej
    Kee, Terence
    Wong, Hin Seng
    Kenmochi, Takashi
    Amante, Angel Joaquin
    Shu, Kuo-Hsiung
    Ingsathit, Atiporn
    Bernhardt, Peter
    Hernandez-Gutierrez, Maria Pilar
    Han, Duck Jong
    Kim, Myoung Soo
    CLINICAL TRANSPLANTATION, 2021, 35 (10)
  • [45] Analysis of Renal Function in Everolimus/Enteric-Coated Mycophenolate Sodium Treated De Novo Renal Transplant Recipients after Calcineurin Inhibitor Withdrawal: The ZEUS Study.
    Budde, K.
    Becker, T.
    Arns, W.
    Sommerer, C.
    Reinke, P.
    Eisenberger, U.
    Fischer, W.
    Kramer, S.
    Pietruck, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 259 - 259
  • [46] TRANSFORM: A NOVEL STUDY TO EVALUATE THE EFFECT OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITORS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: BASELINE DATA
    Pascual, Julio
    TRANSPLANT INTERNATIONAL, 2015, 28 : 442 - 442
  • [47] Effects of the De Novo use of Everolimus with Reduced Calcineurin Inhibitor on Wound Healing Events in the TRANSFORM Study
    Citterio, Franco
    Watarai, Yoshihiko
    Mulgaonkar, Shamkant
    Uyen Huynh-Do
    Bernhardt, Peter
    Henry, Mitchell
    TRANSPLANTATION, 2018, 102 : S94 - S94
  • [48] Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study
    Ganschow, Rainer
    Ericzon, Bo-Goran
    Dhawan, Anil
    Sharif, Khalid
    Martzloff, El-Djouher
    Rauer, Barbara
    Ng, Jennifer
    Lopez, Patricia
    PEDIATRIC TRANSPLANTATION, 2017, 21 (07)
  • [49] RENAL FUNCTION IN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM TREATED DE NOVO LIVING RENAL TRANSPLANT RECIPIENTS AFTER CALCINEURIN INHIBITOR WITHDRAWAL: SUBGROUP ANALYSIS OF THE ZEUS STUDY
    Lehner, F.
    Arns, W.
    Reinke, P.
    Eisenberger, U.
    Paulus, E. -M.
    Scheidl, S.
    Witzke, O.
    Budde, K.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 50 - 51
  • [50] Calcineurin inhibitor-avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients
    Asberg, Anders
    Midtvedt, Karsten
    Line, Pal Dag
    Narverud, Janicke
    Holdaas, Hallvard
    Jenssen, Trond
    Reisaeter, Anna V.
    Johnsen, Linda F.
    Fauchald, Per
    Hartmann, Anders
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 264 - 264
12345